Clinical Evaluation of SARS-COV-2 (COVID-19), Influenza and RSV 8-Well MT-PCR Panel for In Vitro Diagnostics

NAUnknownINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

February 29, 2024

Study Completion Date

February 29, 2024

Conditions
Respiratory Viral Infection
Interventions
DIAGNOSTIC_TEST

SARS-COV-2, Influenza and RSV 8-Well MT-PCR Panel

The SARS-CoV-2, Influenza and RSV PCR test is multiplex-tandem polymerase chain reaction (MT-PCR) based on qualitive in vitro diagnostic testing for the detection and identification of pathogens in nucleic acid extracts.

DIAGNOSTIC_TEST

BioFire Respiratory Panel 2.1

The BioFire Respiratory Panel 2.1 (RP2.1) is a PCR-based multiplexed nucleic acid test intended for use with the BioFire® FilmArray® 2.0 or BioFire® FilmArray® Torch Systems for the simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs (NPS) obtained from individuals suspected of respiratory tract infections.

Sponsors
All Listed Sponsors
lead

AusDiagnostics Pty Ltd.

INDUSTRY

NCT05946538 - Clinical Evaluation of SARS-COV-2 (COVID-19), Influenza and RSV 8-Well MT-PCR Panel for In Vitro Diagnostics | Biotech Hunter | Biotech Hunter